Ex vivo T cell differentiation in adoptive immunotherapy manufacturing: Critical process parameters and analytical...

Area of Science:

• Immunology
• Biotechnology
• Cell Therapy Manufacturing

Background:

• Adoptive immunotherapy holds significant promise for treating cancer and other diseases.
• Therapeutic efficacy of cell-based therapies can be improved by enriching less-differentiated T cell subpopulations.
• This necessitates advanced manufacturing technologies that regulate T cell differentiation.

Purpose of the Study:

• To review critical process parameters (CPPs) and process analytical technologies (PATs) that influence T cell differentiation.
• To emphasize their impact on enriching less-differentiated T cell populations for adoptive immunotherapy.
• To identify limitations in current technologies and suggest future directions.

Main Methods:

• Examination of critical process control parameters including cytokines, metabolites, amino acids, and culture environment.
• Review of advanced process analytical technologies (PATs) for monitoring these parameters.
• Analysis of the impact of these parameters and PATs on T cell differentiation ex vivo.

Main Results:

• Modifying specific process parameters can effectively manipulate T cell differentiation in cultures.
• Advanced PATs are essential for monitoring differentiation and process control.
• Current technologies have limitations in precisely controlling and assessing T cell differentiation.

Conclusions:

• Further development of stringent CPPs and specific at-line/online PATs is crucial.
• These advancements will enable the manufacturing of more effective adoptive immunotherapy products.
• Optimizing T cell differentiation is key to enhancing cell-based therapies.